Oral Psoriasis Treatments: New IL-23 Pills For 2025

For decades, patients with moderate-to-severe plaque psoriasis faced a challenging treatment landscape. While injectable biologic medications offered superior skin clearance outcomes, their requirement for regular injections or infusions created barriers to adherence and patient satisfaction. The emergence of oral psoriasis medications now promises to revolutionize how dermatologists and patients approach disease management, combining the convenience of a daily pill with efficacy levels previously achievable only through injectable therapies.

Understanding the Treatment Gap in Psoriasis Management

Psoriasis represents a significant clinical challenge affecting millions worldwide. Moderate-to-severe plaque psoriasis, characterized by extensive skin involvement and systemic inflammatory responses, traditionally required systemic interventions beyond topical treatments. Traditional oral immunosuppressants, while effective for some patients, carried risks of organ toxicity and required regular monitoring.

The advent of biologic therapies revolutionized psoriasis treatment by targeting specific immune pathways, particularly interleukin-23 (IL-23) and other cytokines driving disease pathogenesis. However, injectable biologics present significant limitations: patient reluctance regarding needle administration, the need for healthcare visits, potential injection site reactions, and the overall burden of parenteral therapy prevented many suitable candidates from initiating treatment.

Earlier oral alternatives, including phosphodiesterase-4 inhibitors and selective tyrosine kinase-2 inhibitors, provided convenient dosing but demonstrated inferior skin clearance compared to injectable biologics. This gap between efficacy and convenience created an unmet clinical need that pharmaceutical innovation is now addressing.

The Innovation Wave: First-in-Class Oral Peptide Inhibitors

A paradigm shift is underway with the development of novel oral peptide inhibitors targeting the IL-23 receptor. These agents represent a fundamentally different approach from earlier small-molecule oral therapies, leveraging peptide technology to achieve biologic-level potency while maintaining the convenience factor of oral administration.

The clinical development of these medications has been unprecedented in scope and rigor. Multiple Phase 3 studies, collectively termed the ICONIC clinical program, have evaluated efficacy across diverse patient populations and challenging treatment scenarios. The program encompasses:

• Studies in adults with moderate-to-severe plaque psoriasis
• Trials specifically including adolescent patients aged 12 years and older
• Investigations focused on difficult-to-treat anatomical sites including scalp, genitalia, palms, and soles
• Long-term safety and durability assessments extending beyond 52 weeks
• Head-to-head comparisons with existing oral agents

Clinical Efficacy: Achieving Biologic-Level Results

The clinical trial outcomes for these oral IL-23 receptor inhibitors have consistently demonstrated impressive efficacy metrics. In Phase 3 studies, nearly 75% of patients achieved clear or almost clear skin status after 24 weeks of treatment, a response rate comparable to or exceeding that of injectable IL-23 biologics.

Primary efficacy endpoints included achievement of Investigator’s Global Assessment (IGA) 0/1, indicating clear or almost clear skin with at least a 2-grade improvement from baseline, as well as Psoriasis Area and Severity Index (PASI) 90 responses, representing 90% improvement in disease severity. The results across the development program demonstrated superiority compared to existing oral agents.

In direct comparisons with deucravacitinib, a previously approved selective tyrosine kinase-2 inhibitor, oral IL-23 receptor inhibitors showed significant advantages. Clinical trial data indicated that 24% of patients receiving the novel oral peptide achieved a symptom score of zero on the Psoriasis Symptoms and Signs Diary at week 16, compared to only 9% in the deucravacitinib group, highlighting substantial differences in patient-reported outcomes.

Response trajectories continued to improve through week 24 and beyond, with PASI 100 achievement rates (complete skin clearance) demonstrating comparable performance to injectable IL-23 biologics, despite the absence of formal head-to-head trials with those agents.

Expanding Access: Treatment for Challenging Anatomical Sites

A particularly important clinical application involves treating psoriasis in anatomically difficult areas. Scalp psoriasis, genital psoriasis, palmoplantar psoriasis, and other sites with natural skin folds present unique therapeutic challenges due to reduced medication penetration, increased friction, and higher rates of secondary infection.

Phase 3 trials specifically evaluating oral IL-23 receptor inhibitors in these difficult-to-treat areas demonstrated statistically significant improvements (p<0.001), with many patients achieving clinically meaningful disease control in regions resistant to conventional therapies. This capability addresses a significant clinical gap, as traditional treatments often prove insufficient for these anatomical zones.

Safety and Tolerability Profile

A cornerstone of the approval pathway for these medications is their favorable safety profile. Clinical trial data indicates that adverse events reported by patients receiving oral IL-23 receptor inhibitors occur at rates similar to placebo, suggesting excellent tolerability. The most commonly observed adverse events include nasopharyngitis and upper respiratory tract infections, which are generally mild and manageable.

The safety profile extends across diverse populations, including adolescent patients aged 12 years and older who were included in Phase 3 trials based on the favorable adult safety data. Long-term follow-up data from trials extending 52 weeks or longer continue to support the sustained safety of these agents, with no emerging safety signals or unexpected toxicities.

This favorable safety profile contrasts favorably with traditional systemic immunosuppressants, which require regular laboratory monitoring for organ toxicity, and distinguishes these agents in the treatment algorithm for moderate-to-severe psoriasis.

Regulatory Pathway and Approval Timeline

The regulatory approval process for oral IL-23 receptor inhibitors has progressed rapidly, reflecting both the clinical significance of these agents and the robust data supporting their safety and efficacy. Johnson & Johnson submitted a New Drug Application to the FDA in July 2025, marking a pivotal moment in psoriasis therapeutics. The submission included an unprecedented data package from four Phase 3 studies, all meeting their primary and secondary endpoints.

The comprehensive submission strategy included head-to-head superiority data versus existing oral agents, efficacy in difficult-to-treat anatomical sites, and pediatric efficacy and safety data. Additionally, Johnson & Johnson initiated the ICONIC-ASCEND trial, representing the first-ever head-to-head comparison between an oral agent and an injectable biologic, comparing icotrokinra to ustekinumab. This innovative trial design addresses a critical evidence gap in the field.

Complementary Advances in Oral Psoriasis Therapy

While IL-23 receptor inhibition represents one significant advancement, the oral psoriasis treatment landscape is expanding through multiple mechanisms. Next-generation selective tyrosine kinase-2 inhibitors, maintaining 24-hour pathway inhibition, are advancing through clinical development with promising Phase 3 data. These agents offer an alternative oral option targeting distinct immune pathways.

The diversity of oral treatment mechanisms allows dermatologists to personalize therapy selection based on individual patient factors, disease phenotype, and treatment goals. Multiple oral options will enable optimization of the treatment algorithm, permitting sequential or alternative approaches should individual agents prove suboptimal.

Clinical Decision-Making and Treatment Selection

The availability of effective oral treatments fundamentally changes clinical decision-making for moderate-to-severe plaque psoriasis. Key considerations in treatment selection include:

• Patient preference for oral versus injectable administration
• Efficacy requirements and skin clearance goals
• Individual comorbidities and safety considerations
• Prior treatment responses and medication history
• Anatomical distribution and specific sites requiring treatment
• Long-term sustainability and durability expectations

For patients previously reluctant to initiate biologic therapy due to needle phobia or injection burden, oral alternatives offering comparable efficacy represent a transformative option. The ease of once-daily oral dosing enhances medication adherence, a critical factor in achieving sustained disease control.

Impact on Patient Outcomes and Quality of Life

Beyond skin clearance metrics, effective psoriasis treatment profoundly impacts patient quality of life. Psoriasis frequently causes psychological distress, social stigma, and functional impairment affecting work, relationships, and mental health. The availability of highly effective oral treatments that patients find acceptable and convenient promotes treatment initiation and adherence.

Patient-reported outcome data from clinical trials demonstrates significant improvements in symptom scores and quality-of-life measures with oral IL-23 receptor inhibition, supporting these medications’ impact on the overall disease burden experienced by patients. When treatment can be administered as a simple daily pill without healthcare visits, patients experience reduced burden and improved satisfaction.

Future Directions and Emerging Therapies

The current era of oral psoriasis therapeutics represents just the beginning of a broader transformation in dermatologic care. Additional oral agents targeting complementary immune pathways are advancing through clinical development. The ICONIC-ASCEND trial comparing oral therapy to injectable biologics will provide critical evidence regarding the comparative positioning of these agents within the treatment hierarchy.

As additional oral options gain approval, combination therapy approaches may emerge, allowing synergistic targeting of multiple immune pathways in treatment-resistant cases. The expanding armamentarium of oral therapies will increasingly permit personalized, precision-medicine approaches to psoriasis management.

Accessibility and Real-World Implementation

The transition from clinical trial efficacy to real-world implementation depends on multiple factors including insurance coverage, medication pricing, patient education, and physician familiarity with novel agents. Dermatology and primary care providers will require training regarding optimal patient selection, dosing strategies, and monitoring approaches for these medications.

However, the profound advantages of oral administration—convenience, reduced healthcare burden, and improved patient acceptability—position these medications to achieve rapid uptake and widespread adoption once regulatory approval is secured and practical implementation pathways are established.

Frequently Asked Questions

Similar Articles

Alarming Rise in Self-Harm in Young People

Alarming Rise in Self-Harm in Young People

Skin Signs Of Non-Accidental Injury: Expert Guide For Clinicians

Lichen Simplex Of The Scrotum: Diagnosis And Treatment

Labial Adhesion In Prepubertal Girls: What Parents Need To Know

Thrush In Men: 5 Signs, Causes, And Treatment Options

Author

Sneha TeteBeauty & Lifestyle Writer

 

Sneha is a relationships and lifestyle writer with a strong foundation in applied linguistics and certified training in relationship coaching. She brings over five years of writing experience to renewcure,  crafting thoughtful, research-driven content that empowers readers to build healthier relationships, boost emotional well-being, and embrace holistic living.

Read full bio of Sneha Tete